-+ 0.00%
-+ 0.00%
-+ 0.00%

PRIME MEDICINE ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PHASE 1/2 CLINICAL TRIAL OF PM577A FOR H1069Q-MUTATED WILSON DISEASE

Reuters·10/05/2026 12:03:03